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In the absence of a complete prevention or cure for diabetes mellitus in all its forms, 
complications will occur in most people with diabetes. These are common and varied. 
The spectrum includes psychosocial as well as biological complications and they may be 
acute, as in those causing very low or high blood glucose. Chronic biological end-organ 
complications of diabetes include so-called microvascular complications of diabetic 
eye, kidney and nerve disease and the macrovascular complications of cardiovascular, 
cerebrovascular and peripheral vascular disease. Evidence from clinical trials indicates that 
using current healthcare and therapy standards, much can be done to prevent onset and 
progression of diabetes complications; indeed, over recent years, serial reductions in death 
rates in people with diabetes reflect such beneficial outcomes. This chapter will focus on 
trends and options in care as well as therapies that hold promise to improve complications 
outcomes in people with diabetes. 
The spectrum of diabetes complications
Diabetes mellitus is essentially a syndrome where the hormone insulin is deficient in the 
body. As a result there is not enough insulin to prevent increases in blood glucose, or to 
normally regulate protein and body fat [1]. While blood glucose levels may be quite mildly 
elevated at certain times in some people with diabetes, if insulin is severely lacking it can 
rapidly lead to emergency, life-threatening conditions of diabetic ketoacidosis, where acid 
in the blood occurs, or hyperosmolar coma where blood glucose levels rise to very high 
levels and may cause coma [2].
A major breakthrough occurred in diabetes care when insulin was discovered as the 
hormone produced by the pancreas which is deficient in diabetes. A short time after that 
discovery in the early 1920s, people with diabetes, especially young children, had their 
lives saved by insulin injection treatment and emergency conditions such as diabetic 
ketoacidosis (DKA) were largely avoided, and quality of life was significantly improved [3]. 
The source of the insulin was initially isolated from animal pancreas, and was subsequently 
derived from human insulin made in the laboratory. However, after the discovery of insulin 
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and its lifesaving role in therapy, it became increasingly clear over the subsequent years and 
decades that people with diabetes were at increased risk of developing a series of different 
complications from diabetes [4], namely damage to certain organs and tissues, especially 
the eyes, kidneys, nerves, heart and blood vessels. These complications are listed in Table 
1. Research into the cause of diabetes complications and the mechanisms to prevent, detect 
and treat them, is the main focus of this chapter.
Table 1. The spectrum of diabetes complications, including acute and chronic, organic and 
psychosocial.
Time course Complication 
grouping
Specific complications
Acute 
(usually hours to days)
Insulin lack diabetic ketoacidosis, hyperosmolar non-
ketotic coma
Insulin excess Hypoglycaemia
Chronic 
(usually years)
Microvascular Diabetic retinopathy, diabetic 
nephropathy, diabetic neuropathy
Macrovascular Cardiovascular disease, cerebrovascular 
disease, peripheral arterial disease
Other (see text for 
detailed list)
Including congenital malformations
Psychsocial General Depression, eating disorder
Diabetes specific Diabetes distress
Acute complications of diabetes
(i) Acute complications due to a lack of insulin 
Amongst the three main types of diabetes mellitus  – type 1, type 2, and gestational diabetes 
– the former two in the absence of a pancreas transplant, are incurable and persist, whereas 
the latter condition is transient. In type 1 diabetes there is absolute insulin deficiency. 
This means that in the absence of insulin therapy, cells in the body will become starved 
of glucose. Insulin is an important anabolic, or building-up, hormone that helps blood 
glucose move into tissues, and cells to create cellular energy, and it prevents breakdown of 
body fats and muscle. Insulin acts like a key to help glucose move into cells. In the complete 
absence of insulin, the cells in the body, especially the liver and skeletal muscle, cannot 
‘see’ glucose outside the cell. As a result, the alternative form of stored glucose, known 
as glycogen, is rapidly broken down by fat and muscle. However glycogen is completely 
used up within 24 hours. The fat and muscle in the body are then broken down and the 
liver takes up fatty acids from the circulation to make an alternative form of energy for 
the body known as keto acids. While these acids, also known as ketone bodies, provide 
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a source of energy to cells, over subsequent hours and days in the absence of any insulin 
the production of keto acids increases to severe levels [2]. The tissues and the circulation 
become progressively acidic, placing the defenses against pH imbalance at these sites under 
great physiologic stress. If the blood glucose is high, the blood is acidic and the blood or 
urine ketones are elevated, then a person is said to have ‘diabetic ketoacidosis’ (DKA). A 
person who develops DKA, will become ‘hot and dry’; he or she will increasingly become 
dehydrated as large volumes of urine are passed due to elevated blood glucose, and will 
often be febrile due to having acid in the blood, causing an elevated body temperature. The 
person with DKA also attempts to breathe off carbon dioxide (CO2) which is formed to 
excess in the body when CO2 is produced from the alkali bicarbonate as a buffer combining 
with the excessive blood acid from ketones. 
DKA is a medical emergency. If it is detected early enough, it can be readily treated with 
intravenous fluid and insulin and restoration of the body’s ions, especially potassium, all 
with close monitoring [5]. Each year in Australia, some people with type 1 diabetes die 
due to diabetic ketoacidosis [6]. The risk of DKA in established type  1 diabetes is 1%–
10% per patient per year [7]. The risk of DKA is increased in people with poor glycaemic 
control or previous episodes of DKA; peripubertal and adolescent girls; children with 
psychiatric disorders, including those with eating disorders; children with difficult or 
unstable family circumstances; children with limited access to medical services; and people 
who omit insulin [7]. Any death due to DKA is a disaster. If treatment is provided early 
enough, mortality should not occur, especially in people who have known type 1 diabetes. 
Increasingly, guidelines to help prevent DKA and to detect this acute complication early 
are being developed [8].
If a person with type 2 diabetes becomes severely deficient in insulin, the blood glucose 
levels may become markedly elevated over subsequent days and weeks [9]. For example, 
some people may develop levels of blood glucose above 50 mmol/L, compared with the 
normal non-diabetic range of about four to eight mmol/L. As blood glucose levels become 
elevated the glucose is lost into the urine, taking water with it and causing dehydration. 
The very high blood glucose levels affect consciousness and can cause confusion, and loss 
of consciousness or coma. This condition known as ‘hyperosmolar non-ketotic coma’, 
(or HONC), is life-threatening. It requires emergency room treatment and intensive care 
support. With careful rehydration and infusion of insulin, as well as treatment of the factor 
that may have destabilised diabetes, such as an infection, most people with HONC will 
survive.
Why people with type 2 diabetes may develop HONC, and yet people with type 1 diabetes 
can develop DKA, is an important clinical observation that has not been fully explained. 
In brief, it appears that in HONC, the body makes enough insulin to prevent keto acid 
formation but not enough to prevent blood glucose rising excessively, whereas the absolute 
insulin lack in type 1 diabetes leads to DKA. It has been observed repeatedly however that 
if some people with type 2 diabetes become severely acutely unwell, for example from a 
severe infection in the body or due to a heart attack (myocardial infarct), then DKA may 
transiently develop or they may develop a mix of HONC and DKA [9]. Distinguishing 
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between type 1 and type 2 diabetes can be difficult and it is increasingly being recognised 
that some people with apparent type 2 diabetes, on careful assessment or in the course of 
time, develop a picture of type 1 diabetes [8].
(ii) Acute complications due to an excess of insulin 
If blood glucose levels fall below the normal range, causing hypoglycaemia, it can make 
a person with diabetes feel unwell, with sweating and tremor and other symptoms, and 
in the most severe situation, loss of consciousness, known as ‘hypoglycaemia coma’. 
Severe hypoglycaemia may be life-threatening, for example, by causing seizure, injury 
or precipitating heart attack or abnormal heart rhythm events [8, 10]. Essentially, 
hypoglycaemia occurs because treatments used for diabetes, either insulin or medications 
that cause increased insulin release from the pancreas, lower blood glucose excessively for 
the needs of the body at a certain point in time [11].
Hypoglycaemia of all forms is, understandably, feared by people with diabetes and their 
immediate carers and family [12]. Fear of hypoglycaemia and its consequences, including 
night-time episodes, is a major barrier to optimal blood glucose control in type 1 diabetes 
and in type 2 diabetes when insulin treatment is required [13]. For most people with 
type 1 diabetes, mild (ie self-treated) hypoglycaemia remains a regular occurrence. It 
may occur about twice weekly [14] and adversely affect quality of life. In contrast, severe 
hypoglycaemia occurs on average once every three or more years in type 1 diabetes [11, 
14]. There is marked individual variation in the rate of severe hypoglycaemia. Some people 
never experience it, whereas in others it occurs multiple times a year, despite intensive 
diabetes support in management [11]. Nocturnal hypoglycaemia accounts for close to half 
of the episodes of severe hypoglycaemia in type 1 diabetes [14]. In type 2 diabetes, for 
people on insulin therapy, mild hypoglycaemia occurs in about 30% of people each year, 
and severe hypoglycaemia in 1%–2% [15]. Risk factors for severe hypoglycaemia in type 1 
and type 2 diabetes include a long duration of diabetes and aiming for tighter blood glucose 
control [8, 11, 15].
Prevention of hypoglycaemia is an important aspect of diabetes care. In people with type 
1 diabetes or type 2 diabetes on therapy that may lower blood glucose such as insulin, 
balancing blood glucose across the day by considering carbohydrate intake, physical activity 
and insulin dosage is a constant consideration [8, 11]. Some forms of insulin therapy and 
diabetes management regimens can help to prevent mild and severe hypoglycaemia. So too 
can insulin pump therapy, especially those that combine state of the art technology with 
real-time continuous blood glucose monitors [8]. 
Treatment of mild hypoglycaemia by oral glucose is usually highly effective, taking 15 to 
20 minutes to begin to have effect [11]. In severe hypoglycaemia causing unconscious, 
intravenous treatment with glucose by a paramedic or a medical doctor, is usually effective. 
Alternatively, a hormone therapy known as glucagon, which mobilises glucose into the 
blood stream from glycogen stores in the liver, can be administered by intramuscular 
injection by a carer who has been educated in the administration, or by a health professional 
[13].
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Table 2. Differing perspectives on diabetes complications.
More negative perspectives More positive perspectives
Diabetes end-organ complications 
occur in most people with diabetes
Most diabetes complications that occur are mild to 
moderate in severity and complications can often be 
detected early and their progression prevented
Due to its high prevalence in 
Australia diabetes is the single 
commonest cause of kidney failure, 
and also working age blindness
Less than 2% of people with diabetes will develop 
end-stage kidney disease or blindness annually
More than 15% of people with 
diabetes will develop at least one 
foot ulcer in their life-time
The vast majority of foot ulcers that occur in people 
with diabetes will heal with proper care without 
requiring extensive amputation
The commonest cause of death 
in people with diabetes is 
cardiovascular disease
Yearly rates of death due to cardiovascular disease in 
people with diabetes have been falling by more than 
50% in developed countries over recent decades, 
due likely to multiple improvements in patient care 
including blood cholesterol, blood pressure and 
blood glucose control
Routine screening for some 
diabetes complications on a regular 
basis is not yet established for 
some conditions such as diabetic 
cardiomyopathy or liver disease 
related to diabetes
Screening for some diabetes complications such as 
diabetic retinopathy, nephropathy and neuropathy 
and foot disease are well established and can help to 
prevent severe complications
Hypoglycaemia is common in 
people with diabetes and is due to 
doses of certain medications such 
as insulin causing an excessive 
lowering of blood glucose
While severe hypoglycaemia is ten to 20 times more 
common in those with type 1 compared with type 
2 diabetes, most hypoglycaemia that occurs in all 
types of diabetes is mild, and severe hypoglycaemia 
can be prevented
Chronic diabetes complications 
Diabetes complications can be divided into those affecting the small vessels of the body, so-
called microvascular, and those affecting the larger vessels termed macrovascular. Micro-
vascular complications are mainly those affecting eyes (diabetic retinopathy), kidneys 
(diabetic nephropathy) and nerves (diabetic neuropathy). Macrovascular complications 
are those of the heart (cardiovascular disease), brain vessels (cerebrovascular disease) and 
the limbs (peripheral arterial disease). There are other diabetes complications which may 
be mixed in type and are discussed subsequently. 
In 2009, diabetes was among the top ten leading causes of death, being the direct cause of 
3% of deaths in Australia, and contributing to another 7.1% of deaths [16]. In addition, the 
presence of diabetes complications increases the financial cost of diabetes at least twofold 
[10]. Diabetes is over-represented as a cause of death in the Indigenous population, where 
it was responsible for 8% of all Indigenous deaths, compared with 2.9% of deaths in non-
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Indigenous people [16]. Probably due mainly to the increased prevalence of diabetes in the 
Australian community, the total number of deaths to which diabetes has contributed has 
progressively increased over the last 20 years [10, 16]. 
(i) Pathogenesis of diabetes complications
Why some organs, and tissues in them, are more susceptible to injury than others is 
not clear and is the subject of ongoing intensive research [17]. However, there are some 
common elements amongst the differing body parts that develop diabetes complications. 
In body sites affected by elevated blood glucose, tissues may become inflamed, or they 
may develop fibrosis/scar tissue or both [18]. Figure 1 indicates a schematic implicating 
biochemical pathways and adverse tissue changes that occur in diabetes complications. 
In inflammation, white cells are attracted into the tissue and inflammatory fluid may 
accumulate. The inflammation is persistent and of low intensity. In other cases the 
native cells in the tissue die and are replaced by scar tissue, also known as fibrosis, which 
involves new blood vessel growth and lay down of proteins termed extracellular matrix 
(ECM). Amongst the organs and tissues affected by diabetes complications, some may 
predominantly develop inflammation, some fibrosis, and others a mixture of the two. For 
example in diabetic nephropathy, there is evidence that inflammation in the kidney then 
leads to fibrosis with loss of kidney function [19]. 
Figure 1. Schematic showing pathogenesis of diabetes complications based on 
biochemical and other cellular pathways activated (tissue injury), and tissue pathological 
change, which may lead to functional loss. High glucose interacts with genetic factors to 
cause tissue injury, tissue cell loss and in some cases, loss of function in a tissue. For 
further explanation refer to the text.
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How elevated blood glucose in diabetes leads to diabetes complications is under intensive 
research [20, 21]. In brief, from a biochemical perspective, high glucose in the blood will 
ultimately diffuse into cells and cause elevated cell glucose. The main biochemical pathway 
that normally handles glucose, known as the glycolytic pathway, and the subsequent 
biochemical pathways known as the TCA cycle and oxidative phosphorylation, become 
overwhelmed by the excess glucose being metabolised and forced into it. As a result, a 
number of changes occur in the biochemistry of cells. The high activity in the oxidative 
phosphorylation pathway leads to dysfunction in the main energy forming part of the 
cell known as the mitochondria and to formation of excessive oxidative stress in cells. In 
addition, a number of overflow metabolic pathways that are not usually very active, become 
much more active as metabolites in the glycolytic pathway accumulate downstream of 
glucose. These overflow pathways include those termed the polyol pathway, the advanced 
glycation end-product pathway, the hexosamine pathway, and the diacylglycerol-protein 
kinase C related pathway [20]. Other factors that may mediate adverse effects of elevated 
glucose in cells and tissues are proteins known as growth factors and cytokines. For 
example, the growth factor known as connective tissue growth factor is induced by all of 
the glucose overflow pathways, and it can cause both inflammation and fibrosis in tissues 
affected by diabetes [18, 19]. Alterations in matrix degradation, in particular by matrix 
metalloproteinases and their regulators, also contribute to tissue damage in diabetes [22–24]. 
Despite the above knowledge, the development of diabetes complications remains 
somewhat of an enigma. Diabetes complications to some degree occur in practically every 
person who develops diabetes, although severe complications occur in only a minority 
[8]. For example, elevated blood and tissue glucose is only one important risk factor for 
diabetes complications. Amongst the microvascular complications, identical twin studies 
have shown that genetic factors account for one-third to one-half the variation in diabetes 
complications, and there are likely both protective genetic factors as well as susceptibility 
factors [25]. To date only some of these genetic factors have been identified. It is thought 
that the interaction between genetic susceptibility with the metabolic effects of elevated 
blood glucose causes the tissue complications of diabetes [21, 25]. It is notable that, while 
increasingly elevated blood glucose levels increase the risk of diabetes complications, 
some people with diabetes can have quite poor blood glucose levels long term and yet they 
develop minimal or no damage to tissues, whereas, in others, mildly elevated blood glucose 
can be associated with severe organ complications.
In addition to elevated glucose, there are other factors that can affect diabetes complications 
risk. Elevated fats, especially saturated fats, and abnormal cholesterol levels with low levels 
of ‘good cholesterol’ (termed high-density lipoprotein cholesterol or HDL-C) and elevated 
and reduced quality ‘bad cholesterol’ (termed low-density lipoprotein cholesterol or LDL-C), 
contribute especially to macrovascular complications risk [26]. Haemodynamic factors, 
especially elevated general body (systemic) blood pressure contribute to both micro- and 
macrovascular complications risk [26, 27]. Increased waist circumference and central body 
fat are associated with high blood pressure, abnormal fats and also resistance to the action 
of insulin. In people who have these characteristic features of insulin resistance, abnormal 
blood fats and cholesterol, and high blood pressure, the ‘insulin resistance’ or ‘metabolic 
360 • A modern epidemic
syndrome’ is said to be present. Presence of the metabolic syndrome increases the risk and 
severity of complications in people with type 1 diabetes [27, 28].
In pregnancy, women who have pre-existing diabetes (type 1 or type 2) are at increased risk 
of having a pregnancy complicated by miscarriage, or certain birth defects, or having large 
babies due to effects of excess blood glucose on the developing fetus [29, 30]. In contrast, 
gestational diabetes, or GDM, develops in later pregnancy (usually 24+ weeks of gestation) 
and likely occurs due to metabolic effects of the placenta and pregnancy placing metabolic 
pressure on the mother’s pancreas. GDM is usually a temporary form of diabetes and the 
elevated blood glucose tendency resolves after delivery. In pregnant women where the 
pancreas cannot make more insulin to overcome insulin resistance of the pregnancy, GDM 
develops. GDM increases the risk, in particular, of large babies at birth, leading potentially 
to obstetric complications at birth, stillbirth, and also increased risk of metabolic syndrome, 
overweight and obesity, and diabetes in later life [31, 32]. GDM also increases the risk of 
development of type 2 diabetes in the mother over subsequent years [32].
Research into diabetes complications occurs at the clinical and pre-clinical levels. As 
end-organ diabetes complications take many years to develop in humans, animal studies 
and cell-based research in the laboratory can help to examine diabetes complications in 
a more timely manner and to test differing interventions to prevent and treat diabetes 
complications [33]. The preclinical studies thus have advantages, although each is only 
a model of human diabetes and its complications, and are what is termed ‘hypothesis 
generating’. Ultimately human clinical studies are required to determine best evidence 
methods to manage diabetes complications. 
(ii) Specific organ diabetes complications described 
A. Microvascular complications
Diabetic retinopathy
In the course of time, most people with diabetes will develop some form of change to 
the back of the eye (retina) [34]. The most common and non-vision-threatening type of 
diabetic retinopathy is termed ‘non-proliferative’, where neither growth of new vessels 
or severe leakiness of the retina is a concern. There are two vision-threatening types of 
diabetic retinopathy. One is proliferative, where new and fragile vessels grow in the retina, 
possibly as a result of poor oxygen supply from damaged initial blood vessels in the retina. 
The other, and most common, type of vision-threatening diabetic retinopathy is diabetic 
macular oedema where excessive leakiness of vessels occurs in the part of the retina that 
is critical to high-quality vision acuity termed the macula (and more centrally the fovea) 
[34]. In Australia, while diabetes remains the commonest cause of blindness in people of 
working age, less than 1% of people per year will develop blindness due to diabetes [35]. 
Diabetic nephropathy
While in each year only about 2% of people with diabetes develop very end-stage kidney 
disease (stage 5 chronic kidney disease), because diabetes mellitus is so common, diabetic 
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nephropathy is the single commonest cause of end-stage kidney disease in Australia 
[35]. The damage to the kidney in diabetes may cause a progressive protein leak termed 
albuminuria, and also in the course of time, loss of kidney-filtering function (loss of the 
glomerular filtration rate). It is the combination of progressive albuminuria/proteinuria 
and loss of glomerular filtration rate that most clearly characterises diabetic nephropathy. 
It is thought that up to 30% of people with diabetes, in the course of time, will develop 
some nephropathy [36, 37]. In the early stages, small amounts of albumin loss in the 
urine, known as microalbuminuria, occur. Subsequently, the albumin and protein loss in 
the urine becomes more marked, and renal filtration function is lost. People with diabetic 
nephropathy not only have an increased risk of end-stage kidney failure developing but 
also increased cardiovascular disease risk – heart attack and heart failure [37].
Diabetic neuropathy
The commonest form of nerve damage in diabetes is to those supplying the feet. The 
sensory nerves are damaged more severely than the motor nerves. Loss of sensation in the 
feet increases the risk of foot ulceration in people with diabetes, and in their lifetime about 
20% of people with diabetes will develop a foot ulcer, with less than 10% of these cases 
leading to the need for amputation [38]. In some people with diabetes, the feet and leg 
nerves become irritated and a painful form of neuropathy develops. This can be disabling, 
especially if prolonged, and requires specific medication to control, if not fully relieve, it.
There is debate as to whether the microvessels supplying the nerves (termed the ‘vasa 
nervorum’), or the nerves themselves, are directly affected by elevated glucose, with 
evidence from animal and human studies that both may be involved [38].
In addition to peripheral neuropathy, there are other forms of nerve damage that can occur 
in diabetes. These forms of neuropathy include those involving the automatic nerves of the 
body known as autonomic neuropathy. Autonomic neuropathy can cause heart rhythm 
problems and a proneness to low blood pressure on standing, as well as stomach and bowel 
upset. Rarer forms of neuropathy, which often improve over some months, involve the 
cranial nerves or and the nerve plexus in the pelvis, known as ‘diabetic amyotrophy’ [38]. 
B. Macrovascular complications
Cardiovascular disease 
The commonest cause of death in people with diabetes is heart disease, accounting for 
about half of the deaths [10]. The heart can be affected by disease of the coronary arteries, 
which is increased two- to six-fold in people with diabetes [39]. The presentation of heart 
disease may be through a classic history of chest pain known as angina, although in some 
people with diabetes the symptoms may be more subtle, such as new shortness of breath 
on less exertion.
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Cerebrovascular disease
Lack of blood supply causing stroke is twice as common in people with diabetes as in the 
general population [40]. Large strokes can lead to death or major disability. In contrast, 
recurrent mini-strokes (causing damage to small parts of the brain known as ‘lacunes’), can 
lead over the years to a form of vascular dementia, especially if blood pressure is elevated.
Peripheral artery disease
Peripheral artery disease is more common in people with diabetes. It can cause a number of 
health problems such as calf pain on walking, and delayed healing in people who develop 
foot ulcers, thus increasing the risk of amputation [41]. Smoking markedly increases the 
risk of peripheral artery disease in people with diabetes, and for this and many other 
reasons smoking avoidance and cessation is vital in diabetes care.
C. Other organ complications in diabetes 
There are many other complications that are caused by diabetes or may be related to it. 
Diabetic foot disease occurs due to combinations of neuropathy, peripheral artery disease, 
ulceration and infection and foot deformity [42]. Cataract and glaucoma are increased in 
people with diabetes [34]. Erectile dysfunction (some degree of impotence) is common in 
men with diabetes due to nerve damage and blood vessel injury [43]. Limited joint mobility 
and skin thickening can occur in people with diabetes [44]. Diabetes is known to directly 
adversely affect heart muscle to cause ‘diabetic cardiomyopathy’ in at least one-third of 
people [45]. In type 2 diabetes, fatty liver known as non-alcoholic liver disease occurs in 
most, and diabetes accelerates its rate of deterioration to an inflammatory and scarring 
form known as non-alcoholic steatohepatitis and in some cases across decades, liver 
cirrhosis [46, 47]. People with type 1 diabetes have an increased risk of developing immune 
related conditions that may affect the thyroid gland to cause over- or under-activity, and 
also the small bowel condition known as coeliac disease, which is a where effects of gluten 
in the diet can cause a toxic effect on the bowel [8]. 
(iii) Psychosocial complications in diabetes 
Diabetes places major psychological stress and self-care demands on the person with 
diabetes and the caring family members. People with diabetes have an increased rate 
of clinical depression and eating disorders, which can exacerbate adverse organ effects 
of diabetes and also adversely affect quality of life [8]. Suicide rates may be higher in 
young people with diabetes compared with the general population [6]. There is also 
a diabetes condition known as ‘diabetes distress’ that describes an underlying anxiety 
and psychological unwellness in people with diabetes [8]. Diabetes can adversely affect 
psychosocial development in children and adolescence [8]. The increased frequency of 
these conditions reflects that psychsocial support is commonly indicated in those with 
diabetes. 
Managing diabetes complications in the clinical arena• 363
(iv) Clinical trials data in diabetes complications: metabolic control matters
While elevated blood glucose is a marker for increased diabetes complications risk, it took 
long-term clinical trials to prove that diabetes complications can be prevented by tight 
blood glucose control. Landmark studies in people with type 1 [8, 14] and type 2 diabetes 
[10, 48–52] have shown that better long-term average blood glucose, measured by a blood 
marker termed HbA1c or glycated haemoglobin, leads to reduced diabetes complications 
onset and in those who already have diabetes complications, their worsening. In studies 
varying from three to 10 years in duration, the onset and progression of microvascular 
complications were clearly prevented. For the macrovascular complications, cardiovascular 
events were shown to be prevented in longer-term studies of about 17 years’ duration [53, 
54]. In those longer-term studies, tight blood glucose control in the first six to 10 years 
led to sustained reduction in the subsequent ten years or so, indicating that the body has 
a ‘memory’ effect of elevated blood glucose. This ‘metabolic memory’ is intriguing. Some 
recent preclinical data suggest that glucose regulation of factors that control genes, so-
called epigenetics, is involved in the memory effect [55].
A recent study in type 2 diabetes indicates that very tight blood glucose control long term 
in people with cardiovascular disease may lead to increased mortality [51]. The exact cause 
of death in the study was unclear, although severe hypoglycaemia episodes causing heart 
attacks or abnormal heart rhythms may at least partly explain the increased death rate. This 
study has led to the concept that tight blood glucose control and targets are indicated early 
in diabetes, but in people with a history of cardiovascular disease, especially if they require 
insulin therapy, the blood glucose targets should be more relaxed [10, 56].
(v) Blood pressure and cholesterol control also prevent diabetes complications
A number of important studies in type 1 and type 2 diabetes have shown that blood pressure 
control can prevent onset and worsening of microvascular complications, especially 
diabetic nephropathy and diabetic retinopathy, and all macrovascular complications, 
especially stroke. The class of medications known as angiotensin converting enzyme 
inhibitors and angiotensin receptor antagonists/blockers, appear to have special protective 
roles and are the preferred first-line agents in people with diabetes [57]. Other studies have 
shown that reduction in blood levels of bad (LDL) cholesterol, especially with medications 
known as ‘statins’, even in those without known cardiovascular disease, will reduce the risk 
of cardiovascular complications such as heart attack and stroke [58].
A study of people with type 2 diabetes in Denmark examined whether the combined 
simultaneous targeting of blood pressure, cholesterol and blood glucose would lead to 
improved outcomes [59]. It clearly demonstrated that targeting all three end-points over 
eight years or more, led to a more than 50% reduction in macro- and microvascular 
complications. These studies form the evidence for targeting blood glucose, blood pressure 
and cholesterol in people with diabetes.
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(vi) Screening for diabetes complications
In people with diabetes, there is a clear evidence showing that screening to detect 
certain diabetes complications is important [8, 10]. This is because, in those developing 
complications, some therapies can be intensified to help prevent worsening of the 
complication to its end stages. For example, in diabetic retinopathy, vision-threatening 
forms (proliferative retinopathy or macular oedema) can be treated with laser therapy, 
or intraocular corticosteroids or anti-growth factor therapy, to help prevent vision loss. 
In diabetic nephropathy, even tighter blood pressure control (to less than 125/75 mmHg, 
rather than less than 130/80 mmHg) can help prevent its progression, and in people with 
diabetic foot disease, intensive patient education combined with protective foot wear and 
early treatment of foot ulcers, can help to prevent amputation. 
The screening for diabetic retinopathy requires a thorough examination of the retinae 
and measurement of visual acuity. In diabetic nephropathy, urine tests for albumin and 
in some cases protein, as well as blood tests for renal function (glomerular filtration rate) 
are required. For neuropathy and foot problems, feet need to be carefully examined for 
sensation, pulses and mechanical foot problems as well as ulcers.
In people with type 2 diabetes, microvascular screening for complications should begin 
from diagnosis [10], as a delay in recognition of diabetes and diabetes diagnosis of some 
years is common in type 2 diabetes, and effects of high blood glucose often occur for many 
years before diabetes diagnosis. In type 1 diabetes, screening should occur after about three 
years of diabetes. In each case, screening should usually occur annually thereafter [8].
In terms of macrovascular disease, complications screening is usually by history taking and 
physical examination. The role for extensive heart investigations, including exercise tests, is 
unclear and studies have shown that unless a person has symptoms of heart disease, tight 
blood pressure, blood glucose and cholesterol control, as well as avoidance of smoking and 
possibly blood thinning (anti-platelet) therapy are the cornerstone of care.
In people with type 1 diabetes, screening approximately annually for autoimmune thyroid 
disease and also coeliac disease, each by blood test, is indicated in children and adults [8].
(vii) Major challenges in diabetes complications care
Managing diabetes and its complications has a number of inherent challenges. One 
dynamic tension is that long-term blood glucose control is important to prevent long-term 
organ complications of diabetes, yet tight blood glucose control can increase the risk of 
severe hypoglycaemia, especially in cases where insulin therapy is required, such as in all 
people with type 1 diabetes and in those with type 2 diabetes requiring insulin therapy. 
A second tension is that diabetes place major demands on a person’s lifestyle in terms of 
healthy diet and exercise and, simultaneously, people with diabetes usually need to take 
multiple preventive medications to manage blood glucose, blood pressure and cholesterol. 
The person with diabetes needs to self-monitor blood glucose multiple times daily using a 
finger prick device and people with type 1 diabetes need to inject insulin four to five times 
daily. In people with type 1 diabetes this equates to more than 1000 blood glucose self-tests 
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and more than 1000 insulin injections yearly. Diabetes is unrelenting and does not provide 
any ‘holidays’.
Considering the demands that diabetes places on the person with diabetes and their 
families, the health professional support and healthcare delivery services required are 
extensive and high level. Services for people with diabetes need to be comprehensive yet 
individualised in their targets and emphasis [8, 10, 56, 60]. Multidisciplinary healthcare 
teams are required, involving a skilled doctor, diabetes nurse educator or practice nurse, 
and dietitian. In type 1 diabetes and complex type 2 diabetes, to support the general 
practitioner, an endocrinologist is indicated to help lead chronic care. Other members 
of the diabetes healthcare team will often include the podiatrist, exercise physiologist, 
psychologist or psychiatrist, orthotist, foot and vascular surgeon, renal physician, 
ophthalmologist, cardiologist and microbiologist. Care of the person with diabetes thus 
requires highly coordinated care in order to optimise targets in therapy and to ensure that 
regular diabetes complications screening is undertaken [8, 10, 56, 60].
(viii) Transplantation and diabetes complications
Kidney transplant is often an option in a person with diabetes who has end-stage renal 
failure requiring dialysis. Outcomes are good if cardiovascular disease and heart failure 
is not severe in a patient. Kidney transplant can be combined with pancreas transplant 
in some cases, resulting in reduced need for insulin therapy and a reduction in severe 
hypoglycaemia. There is also evidence that some forms of neuropathy and kidney disease 
can improve after pancreas transplant [61].
(ix) Reversibility of diabetes complications
While most diabetes complications are progressive, some are transient. The microvascular 
complications of diabetes may in some cases regress, especially with intensive therapy. 
For example, diabetic nephropathy in its early micro-albuminuria stages may regress to 
normo-albuminuria with treatment of blood pressure [62], and painful diabetic neuropathy 
symptoms may resolve with time and improved blood glucose control, as may early diabetic 
retinopathy. Even some changes of fibrosis in tissues such as the kidney may become less 
marked with tight control of blood pressure and blood glucose in diabetic nephropathy [61]. 
Most studies in diabetes complications to date have examined prevention of progression 
rather than regression of complications.
(x) Diabetes and obstetric care
It is beyond the scope of this chapter to address obstetric aspects of diabetes in detail. It 
should be noted however that in women with type 1 or type 2 diabetes, tight control of 
blood glucose before conception and across a pregnancy can lead to marked reduction in 
birth defects, stillbirth and large-at-birth babies [29, 30]. Outcomes are also improved for 
the baby in a mother with gestational diabetes, in terms of reduced complications at birth 
and possibly, less stillbirth [31]. The data from series of high quality studies, including 
Australian clinical trials [31], provides reassuring data that much can be achieved to 
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prevent diabetes complications in pregnancies complicated by diabetes, whether it be type 
1, type 2 or gestational diabetes in the mother.
(xi) Outcomes are improving in diabetes complications
Data from multiple databases in Australia and other developed countries have indicated 
that the rate of death in people with diabetes has reduced over the decades in both type 1 
and type 2 diabetes [63, 64]. Factors that have likely contributed to this beneficial outcome 
include the increasing evidence to support more intensive control of cholesterol (with 
statins), blood pressure (with angiotensin converting enzyme inhibitors or angiotensin 
receptor blocker therapy) and blood glucose in people with diabetes, and possibly more 
complete screening for diabetes complications. Reductions in smoking rates have also 
likely helped. However, people with diabetes continue to have a reduced life expectancy 
on average compared with an age-matched general population and the earlier diabetes 
onset occurs, the greater the reduction in average life expectancy due to diabetes-related 
complications [63, 10]. This, combined with the end-stage complications that occur in 
diabetes and the morbidity complications caused and related healthcare costs [8, 10], 
demand no complacency in diabetes complications detection and its management.
(xii) Prospects in diabetes complications and related care
It is envisaged that healthcare services delivery will progressively be enhanced to ensure 
that most if not all people with diabetes have complications screening as clinically indicated 
and that they have their major risk factors of blood pressure, cholesterol and blood glucose 
tightly and safely controlled. 
It may also be the case that an increasing focus on regression of diabetes complications will 
indicate whether actual regression of changes should be a target in treatment rather than 
just the prevention of worsening of complications. For example, regression of albuminuria 
may be shown in the course of time to predict fewer kidney and cardiovascular events than 
stabilisation of albuminuria levels alone. It may well be that our treatment of blood pressure 
improves with increasing and new combination of agents, as will our control of both good 
and bad cholesterol through combined therapies. In type 1 and type 2 diabetes improved 
knowledge in healthcare delivery and advances in technology, such as more sophisticated 
insulin pumps and blood glucose monitoring, will likely further help to improve long-
term blood glucose diabetes and thus prevent organ complications and minimise severe 
hypoglycaemia. 
Considering the adverse effects of high blood glucose on cells and cellular pathways to cause 
tissue injury (Figure 1), it is envisaged that therapies targeted at, for example, growth factors 
may increasingly help to prevent, stabilise and possibly reverse diabetes complications. Such 
is already being realised in diabetic retinopathy where anti-vascular endothelial growth 
factor therapy is becoming a reality for vision-threatening retinopathy to complement 
the traditional treatment of laser photocoagulation therapy [34]. As described in other 
chapters, the agent fenofibrate is showing remarkable effects in preventing microvascular 
complications of diabetes [65].
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Lastly, as interventions for diabetic cardiomyopathy in prevention of heart failure and 
diabetes and liver disease develop, it is envisaged that screening for these two conditions 
will improve. Worldwide, despite the epidemic of obesity and diabetes, increased access 
to insulin and blood glucose monitoring through programs such as Insulin for Life [66], 
and to skilled teams of healthcare professionals, through the support of the International 
Diabetes Federation and United Nations spearheaded campaigns, are expected to improve 
global outcomes in diabetes.
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